Atricure Inc. Stock
Atricure Inc. Stock
A loss of -1.700% shows a downward development for Atricure Inc..
Atricure Inc. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 44 € there is a positive potential of 27.17% for Atricure Inc. compared to the current price of 34.6 €.
Pros and Cons of Atricure Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atricure Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atricure Inc. | -1.700% | 24.460% | 39.516% | -44.194% | 1.765% | -44.194% | -51.944% |
| Orthofix Medical Inc. | -4.330% | 6.417% | 20.606% | 1.015% | -22.868% | -42.486% | -69.099% |
| Lantheus Holdings Inc | 0.920% | -3.947% | -9.877% | 39.269% | 53.147% | 9.802% | - |
| Natera Inc | -0.510% | 0.694% | -2.356% | 96.695% | 17.817% | 442.290% | 145.608% |
Comments
AtriCure (ATRC) was given a new $50.00 price target by UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Wall Street Zen from "buy" to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
AtriCure (ATRC) was upgraded by Freedom Capital to "strong-buy".
Show more
Ratings data for ATRC provided by MarketBeat
News
AtriCure Q2 Earnings Call Highlights
Key Points
- Interested in AtriCure, Inc.? Here are five stocks we like better.
- AtriCure posted strong Q2 2026 results, with revenue up 12.8% to $153.6 million and a return to GAAP
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
This medical device innovator for cardiac surgery reported an insider sale amid a year of negative total returns.
Doraiswamy Vinayak, Chief Scientific Officer of AtriCure (NASDAQ:ATRC), reported the
